2592 — Cloudbreak Pharma Balance Sheet
0.000.00%
Last trade - 00:00- HK$4.45bn
- HK$7.48bn
- $10.00m
Annual balance sheet for Cloudbreak Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 79.1 | 60.2 | 34.9 |
| Net Total Receivables | 0.813 | 0.774 | 2.09 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 80.1 | 61.5 | 37.5 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 1.17 | 3.27 | 2.43 |
| Other Long Term Assets | |||
| Total Assets | 82.1 | 64.8 | 40 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 227 | 327 | 391 |
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Liabilities | 227 | 328 | 392 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | -145 | -263 | -352 |
| Total Liabilities & Shareholders' Equity | 82.1 | 64.8 | 40 |
| Total Common Shares Outstanding |